Innovation Pharmaceuticals Inc (IPIX)

[mdphd2008]

Although the primary endpoint was not met. It is possible a secondary endpoint such as mortality may have been met.

This was alluded to in the press release:

“The number of patients who died totaled eight, four each between active and placebo.”

“In the trial, 120 patients were treated, with three-fourths receiving 5 days of study drug.”

If the majority of patients were treated with Brilacidin - proportionately more patients should be dying in the Brilacidin group if mortality rates were equivalent.

However, it was equivalent numbers of patients dying (NOT equivalent percentages).

That translates to a potential reduction in mortality in the Brilacidin group!!

I truly and honestly wish primary endpoint was met and I will admit I was hopeful. However, I am NOT selling any shares until we get additional data of secondary endpoints.